Moderna - Yahoo Search Results

- Why Moderna Was a Roller Coaster Today | The Motley Fool
  The Motley Fool· 14 hours ago
  Moderna (NASDAQ:MRNA) provided an up-and-down ride for its investors on Friday, with the stock...
- Good news about the 'Moderna arm' vaccine rash — it's no worse with second shot
  USA TODAY via Yahoo News· 3 days ago
  There's good news about "Moderna arm," the raised, sometimes itchy red rash some people get a week...
- Detroit mayor rejects initial J&J vaccine shipment, saying Pfizer and Moderna are 'the best'
  CNBC· 21 hours ago
  Detroit Mayor Mike Duggan rejected an initial allotment of the single-shot Johnson & Johnson...
- Here's How Moderna Is Ensuring Its Lead in the Coronavirus Vaccine Market | The Motley Fool
  The Motley Fool· 4 days ago
  As you might have guessed (thanks to the headline of this article), I'm referring to Moderna...
- Is Short-Selling a Risk for Moderna? | The Motley Fool
  The Motley Fool· 2 hours ago
  In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss whether the trend will continue - ...
- 2 Green Flags for Moderna in 2021 and 1 Yellow Flag | The Motley Fool
  The Motley Fool· 3 hours ago
  Moderna (NASDAQ:MRNA) recently reported its first-ever product revenue thanks to coronavirus vaccine sales. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare ...
- Moderna's CEO Calls These 3 Elements "Critical" for Vaccine Success
  Motley Fool· 3 days ago
  Moderna (NASDAQ: MRNA) has been among the first to address the biggest challenge facing coronavirus...
- Dr. Fauci has a stunningly simple way to explain how Johnson & Johnson's COVID-19 vaccine differs...
  Business Insider via Yahoo News· 3 days ago
  Pfizer's and Moderna's are mRNA-based, while Johnson & Johnson's is an adenovirus. Dr. Anthony Fauci...
- Why Moderna Could Be Worth $100 Billion Within 5 Years | The Motley Fool
  The Motley Fool· 2 days ago
  There are only a dozen drugmakers in the world right now with market caps of $100 billion or more. ...
- First Study of Moderna's Variant-Targeted Vaccine May Start Next Week - WSJ.com
  The Wall Street Journal· 20 hours ago
  The first human study to test Moderna Inc.'s new vaccine targeting a concerning Covid-19 strain is...